Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study

Table 4 Immunological responses to highly active antiretroviral therapy

	Baseline		24 wk			48 wk			96 wk
	n	mean CD4 (SD)	n	mean CD4 (SD)	P1 value	n	mean CD4 (SD)	P1 value	n	mean CD4 (SD)	P1 value
FDC	80	698.5 (295.3)	80	730.3 (339.7)	0.173	76	707.6 (281.9)	0.717	73	751.7 (289.9)	0.011
Atripla	30	649.7 (285.2)	30	666.3 (278.3)	0.549	29	709.9 (274.8)	0.032	26	715.0 (286.2)	0.02
Truvada	20	678.8 (261.3)	20	658.9 (263.3)	0.639	17	627.1 (224.8)	0.227	17	741.4 (279.2)	0.145
Kivexa	24	740.8 (356.4)	24	823.0 (460.2)	0.107	24	738.1 (341.0)	0.957	24	773.5 (317.2)	0.518
MTR	163	671.6 (268.9)	159	730.4 (282.0)	< 0.001	137	745.2 (281.0)	< 0.001	117	769.0 (269.0)	< 0.001
TDF/3TC/-EFV	46	665.6 (251.3)	43	742.9 (234.1)	0.003	34	746.0 (261.7)	0.002	30	759.9 (245.7)	< 0.001
TDF/3TC	50	665.7 (311.6)	50	735.7 (341.6)	0.003	44	751.8 (336.2)	< 0.001	40	766.8 (311.4)	< 0.001
ABC/3TC	32	675.4 (202.3)	32	733.7 (225.5)	0.06	29	740.7 (211.9)	0.036	28	810.5 (247.2)	< 0.001

¹Mean CD4 difference vs baseline (Fisher’s LSD test). MTR: Multi-tablet regimen; FDC: Fixed dose coformulation.